Allterum Therapeutics develops targeted therapies for various cancer types utilizing advanced drug delivery systems to enhance treatment efficacy and specificity. The company aims to improve patient outcomes by minimizing the side effects commonly associated with traditional cancer therapies.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CPFounders
Product
Problem
Patients with relapsed/refractory hematologic malignancies, including T-cell ALL and B-cell lymphomas, often face a poor prognosis due to the limited availability of effective treatment options. Additionally, some lymphomas and solid tumors overexpress CD127, but lack targeted therapies to address this specific characteristic.
Solution
Allterum Therapeutics is developing targeted antibody therapies focused on the IL-7 pathway for cancers that express CD127. Their lead candidate is a monoclonal antibody against CD127 (IL-7Rα), designed to provide a much-needed option for patients with relapsed or refractory hematologic malignancies. By targeting the IL-7 axis, Allterum aims to offer a more effective and specific treatment approach for cancers with CD127 over-expression.
Target Audience
The primary target audience includes patients with relapsed/refractory hematologic malignancies, particularly T-cell ALL and B-cell lymphomas, as well as individuals with lymphomas and solid tumors that overexpress CD127.
Features
- Focus on developing monoclonal antibody therapies
- Targeting the IL-7 pathway and CD127 expressing cancers
- Initial focus on relapsed/refractory T-cell ALL and B-cell hematologic malignancies
- Actively identifying other cancers with CD127 over-expression that may benefit from treatment